Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 9/20 | 0.59 |
| ▸ | PRKCB | P05771 | 7/20 | 0.59 |
| ▸ | PRKACA | P17612 | 7/20 | 0.59 |
| ▸ | PRKACG | P22612 | 7/20 | 0.59 |
| ▸ | PRKACB | P22694 | 7/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.59 |
| ▸ | PRKCH | P24723 | 3/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.59 |
| ▸ | CDK1 | P06493 | 3/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.59 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.59 |
| ▸ | CDK4 | P11802 | 3/20 | 0.59 |
| ▸ | CCND1 | P24385 | 3/20 | 0.59 |
| ▸ | PIM1 | P11309 | 2/20 | 0.59 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006054 | 0.95 | PRKCA (0.64) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| SCHEMBL7009039 | 0.84 | PRKACA (0.62) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| Acetic Acid SCHEMBL7014928 | 0.83 | PRKCB (0.54) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| SCHEMBL7007889 | 0.82 | CAMK2D (0.62) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| Trifluoroacetic Acid SCHEMBL7011017 | 0.81 | CAMK2D (0.54) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| SCHEMBL7005539 | 0.79 | CDK4 (0.55) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| SCHEMBL7005333 | 0.78 | PRKCB (0.56) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| SCHEMBL16576315 | 0.77 | PRKACA (0.72) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| Trifluoroacetic Acid SCHEMBL6983051 | 0.76 | CAMK2D (0.46) | PRKCAPRKCBPRKACAPRKACGPRKACB | |
| SCHEMBL7815621 | 0.75 | PRKACA (0.81) | PRKCAPRKCBPRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | ASTRAZENECA AB, A SWEDISH CORPORATION | 2003-07-17 | — | — | US | disclosed |
| EP-1042317-B1 | Indole derivatives as PKC-inhiboitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-6492409-B1 | SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| US-6337342-B1 | ARYLIMIDAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | HTR3C, HTR6, CNR1 | PRKCA 3822/4885PRKCB 3108/4885PRKACA 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.